Overview

Asia Pacific Pharmaceutical Contract Manufacturing Market is estimated to register a CAGR of over 7.6% during the forecast period 2020 to 2027

FutureWise Market Research has instantiated a report that provides an intricate analysis of Asia Pacific Pharmaceutical Contract Manufacturing Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Asia Pacific Pharmaceutical Contract Manufacturing Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Asia Pacific Pharmaceutical Contract Manufacturing Market:
• Aenova Group
• Baxter BioPharma Solutions
• Boehringer Ingelheim
• Catalent Inc.
• Famar S.A.
• Hospira, Inc.
• Jubilant Life Sciences Ltd.
• Lonza Group
• Patheon Inc.
• Pfizer CentreSource
• Recipharm AB
• Vetter Pharma International GmbH
 (Note: The list of the major players will be updated with the latest market scenario and trends)

Asia Pacific Pharmaceutical Contract Manufacturing Market Segmentation:
By Category
• Pharmaceutical Industry
• Biopharmaceutical Industry

By Product
• Active Pharmaceutical Ingredients (API)
 o Branded API Manufacturing
 o Generic API Manufacturing
• Finished Dosage Formulations (FDF)
 o Solid Dosage
 o Oral Liquids
 o Parenteral/Injectables
 o Other FDFs

By Phase
• Clinical Manufacturing
• Commercial Manufacturing

By Type
• Sterile Products
• Non-Sterile Products

By Therapeutic Application
• Infectious Diseases
• Oncology
• Metabolic Disorders
• Cardiovascular Disorders
• Central Nervous System
• Pulmonary Disorders
• Gastrointestinal Disorders
• Other Therapeutic Applications

By Region
• Japan
• China
• India
• Australia and New Zealand
• ASEAN
• Rest of Asia Pacific

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Asia Pacific Pharmaceutical Contract Manufacturing Market By Category, By Product, By Phase, By Type, By Therapeutic Application and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— Asia Pacific.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
  1.1 Objectives of the Study
  1.2 Market Definition
  1.3 Market Scope
      1.3.1 Years Considered for the Study
      1.3.2 Market Covered
  1.4 Currency
  1.5 Limitations
  1.6 Stakeholders

2. Research Methodology
   2.1 Research Data
       2.1.1 Secondary Data
             2.1.1.1 Key Data from Secondary Sources
       2.1.2 Primary Data
             2.1.2.1 Key Data from Primary Sources
   2.2 Market Size Estimation
   2.3 Market Breakdown and Data Triangulation
   2.4 Assumptions for the Study  

3. Executive Summary
  3.1 Market Outlook
  3.2 Segment Outlook
  3.3 Competitive Insights

4. Global Asia Pacific Pharmaceutical Contract Manufacturing Market Variables, Trends & Scope
  4.1. Market Lineage Outlook
  4.2. Penetration and Growth Prospect Mapping
  4.3. Industry Value Chain Analysis
  4.4. Cost Analysis Breakdown
  4.5. Technology Overview
  4.6. Regulatory Framework
       4.6.1. Reimbursement Framework
       4.6.2. Standards and Compliances

5. Market Overview
  5.1. Market Dynamics
       5.1.1. Market Driver Analysis
              5.1.1.1. Increasing focus of Asia Pacific Pharmaceutical Contract Manufacturing Companies on Brand Protection
              5.1.1.2. Untapped Opportunities in Emerging Regions
       5.1.2. Market Restraint Analysis
              5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
       5.1.3. Industry Challenges
              5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Global Asia Pacific Pharmaceutical Contract Manufacturing Market Analysis Tools
  6.1. Industry Analysis - Porter’s
       6.1.1. Supplier Power
       6.1.2. Buyer Power
       6.1.3. Substitution Threat
       6.1.4. Threat from New Entrants
       6.1.5. Competitive Rivalry
  6.2. Pestel Analysis
       6.2.1. Political Landscape
       6.2.2. Environmental Landscape
       6.2.3. Social Landscape
       6.2.4. Technology Landscape
       6.2.5. Legal Landscape
  6.3. Major Deals And Strategic Alliances Analysis
       6.3.1. Joint Ventures
       6.3.2. Mergers and Acquisitions
       6.3.3. Licensing and Partnership
       6.3.4. Technology Collaborations
       6.3.5. Strategic Divestments
  6.4. Market Entry Strategies
  6.5. Case Studies

7. Global Asia Pacific Pharmaceutical Contract Manufacturing Market, By Category Historical Analysis and Forecast 2020-2027 (USD Million)
  7.1. Pharmaceutical Industry
  7.2. Biopharmaceutical Industry

8. Global Asia Pacific Pharmaceutical Contract Manufacturing Market, By Product Historical Analysis and Forecast 2020-2027 (USD Million)
  8.1. Active Pharmaceutical Ingredients (API)
       8.1.1. Branded API Manufacturing
       8.1.2. Generic API Manufacturing
  8.2. Finished Dosage Formulations (FDF)
       8.2.1. Solid Dosage
       8.2.2. Oral Liquids
       8.2.3. Parenteral/Injectables
       8.2.4. Other FDFs

9. Global Asia Pacific Pharmaceutical Contract Manufacturing Market, By Phase Historical Analysis and Forecast 2020-2027 (USD Million)
  9.1. Clinical Manufacturing
  9.2. Commercial Manufacturing

10. Global Asia Pacific Pharmaceutical Contract Manufacturing Market, By Type Historical Analysis and Forecast 2020-2027 (USD Million)
  10.1. Sterile Products
  10.2. Non-Sterile Products

11. Global Asia Pacific Pharmaceutical Contract Manufacturing Market, By Therapeutic Application Historical Analysis and Forecast 2020-2027 (USD Million)
  11.1. Infectious Diseases
  11.2. Oncology
  11.3. Metabolic Disorders
  11.4. Cardiovascular Disorders
  11.5. Central Nervous System
  11.6. Pulmonary Disorders
  11.7. Gastrointestinal Disorders
  11.8. Other Therapeutic Applications

12. Asia Pacific Pharmaceutical Contract Manufacturing Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
   12.1. Introduction
   12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
         12.2.1. Japan
         12.2.2. China
         12.2.3. India
         12.2.4. Australia and New Zealand
         12.2.5. ASEAN
         12.2.6. Rest of Asia Pacific
   12.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027  

13. Market Share Analysis and Competitive Landscape  
   13.1. Asia Pacific Landscape - Key Players, Revenue and Presence
   13.2. Asia Pacific Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
   13.3. Asia Pacific Emerging Companies
   13.4. Asia Pacific - Market Share Analysis and Key Regional Players
   13.5. Asia Pacific Key Player - Growth Matrix

14. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
   14.1. Aenova Group
         14.1.1. Company Overview
         14.1.2. Product Portfolio
         14.1.3. SWOT Analysis
         14.1.4. Financial Overview
         14.1.5. Strategic Overview
   14.2. Baxter BioPharma Solutions
         14.2.1. Company Overview
         14.2.2. Product Portfolio
         14.2.3. SWOT Analysis
         14.2.4. Financial Overview
         14.2.5. Strategic Overview
   14.3. Boehringer Ingelheim
         14.3.1. Company Overview
         14.3.2. Product Portfolio
         14.3.3. SWOT Analysis
         14.3.4. Financial Overview
         14.3.5. Strategic Overview
   14.4. Catalent Inc.
         14.4.1. Company Overview
         14.4.2. Product Portfolio
         14.4.3. SWOT Analysis
         14.4.4. Financial Overview
         14.4.5. Strategic Overview
   14.5. Famar S.A.
         14.5.1. Company Overview
         14.5.2. Product Portfolio
         14.5.3. SWOT Analysis
         14.5.4. Financial Overview
         14.5.5. Strategic Overview          
   14.6. Hospira, Inc.
         14.6.1. Company Overview
         14.6.2. Product Portfolio
         14.6.3. SWOT Analysis
         14.6.4. Financial Overview
         14.6.5. Strategic Overview      
   14.7. Jubilant Life Sciences Ltd.
         14.7.1. Company Overview
         14.7.2. Product Portfolio
         14.7.3. SWOT Analysis
         14.7.4. Financial Overview
         14.7.5. Strategic Overview
   14.8. Lonza Group
         14.8.1. Company Overview
         14.8.2. Product Portfolio
         14.8.3. SWOT Analysis
         14.8.4. Financial Overview
         14.8.5. Strategic Overview
   14.9. Patheon Inc.
         14.9.1. Company Overview
         14.9.2. Product Portfolio
         14.9.3. SWOT Analysis
         14.9.4. Financial Overview
         14.9.5. Strategic Overview
   14.10.Pfizer CentreSource
         14.10.1. Company Overview
         14.10.2. Product Portfolio
         14.10.3. SWOT Analysis
         14.10.4. Financial Overview
         14.10.5. Strategic Overview
   14.11.Recipharm AB
         14.11.1. Company Overview
         14.11.2. Product Portfolio
         14.11.3. SWOT Analysis
         14.11.4. Financial Overview
         14.11.5. Strategic Overview
   14.12.Vetter Pharma International GmbH
         14.12.1. Company Overview
         14.12.2. Product Portfolio
         14.12.3. SWOT Analysis
         14.12.4. Financial Overview
         14.12.5. Strategic Overview

15. Pre and Post COVID-19 Impact
   15.1. Positive influence on the healthcare industry
   15.2. The financial disruption of the manufacturing sector
   15.3. Impact of COVID-19 on emerging companies
   15.4. Significant mandates in the healthcare regulations initiated by administrations
   15.5. The overall economic slowdown of the developing and developed nations

16. FutureWise SME Key Takeaway Points for Client

Tables

Figures